Top 50 Medical VC Funds & Investors in United Kingdom (May 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
UK Innovation & Science Seed Fund
VC Fund
|
20 | United Kingdom, United States | Seed, Series A | Biotechnology, Health Care, Medical | $246k–$10M |
|
Parkwalk Advisors
VC Fund
|
20 | United Kingdom, United States, Philippines | Seed, Series A, Series B | Biotechnology, Health Care, Software | $860k–$33M |
|
Deepbridge Capital
VC Fund
|
18 | United Kingdom, Australia, Singapore | Seed, Series A | Health Care, Biotechnology, Medical | $143k–$10M |
|
Scottish Enterprise
VC Fund
|
18 | United Kingdom, United States, Japan | Grant, Seed | Biotechnology, Software, Health Care | $92k–$4.1M |
|
Oxford Science Enterprises
VC Fund
|
16 | United Kingdom, United States, The Netherlands | Seed, Series A | Biotechnology, Health Care, Software | $1M–$34M |
|
Oxford Technology Management
VC Fund
|
15 | United Kingdom, United States | Seed, Series A | Biotechnology, Health Care, Software | $25k–$7.4M |
|
Scottish Investment Bank
VC Fund
|
13 | United Kingdom, United States, France | Seed, Series A | Software, Biotechnology, Information Technology | $307k–$7.6M |
|
Archangels
VC Fund
|
13 | United Kingdom, United States | Seed, Series A | Software, Biotechnology, Health Care | $123k–$7M |
|
Mercia Fund Managers
VC Fund
|
13 | United Kingdom, United States, Hungary | Seed, Series A | Software, Health Care, Biotechnology | $184k–$21M |
|
GM&C Life Sciences Fund
VC Fund
|
12 | United Kingdom, Italy, Germany | Seed, Series A | Health Care, Biotechnology, Medical | $61k–$903k |
|
AlbionVC
VC Fund
|
12 | United Kingdom, United States, France | Series A, Seed | Software, Health Care, Artificial Intelligence | $1.8M–$13M |
|
Development Bank of Wales
VC Fund
|
11 | United Kingdom, Australia, United States | Seed, Debt Financing | Health Care, Software, Biotechnology | $12k–$2.8M |
|
Newable Private Investing
VC Fund
|
11 | United Kingdom, United States | Seed, Series A | Software, Health Care, Biotechnology | $184k–$3.8M |
|
Catapult Ventures
VC Fund
|
10 | United Kingdom, United States, Israel | Seed, Series A | Health Care, Biotechnology, Pharmaceutical | $123k–$26M |
|
Oxford Capital
VC Fund
|
10 | United Kingdom, United States, France | Seed, Series A | Software, Mobile, Health Care | $1.6M–$13M |
|
Cambridge Innovation Capital
VC Fund
|
9 | United Kingdom, United States, Ireland | Series B, Series A, Seed | Biotechnology, Health Care, Therapeutics | $614k–$61M |
|
Northstar Ventures
VC Fund
|
9 | United Kingdom, United States, Estonia | Seed, Series A | Software, E-Commerce, Internet | $37k–$8.8M |
|
IP Group
VC Fund
|
9 | United Kingdom, United States, Australia | Seed, Series A, Series B | Health Care, Biotechnology, Therapeutics | $369k–$61M |
|
Nesta Ventures
VC Fund
|
9 | United Kingdom, United States | Seed, Series A | Biotechnology, Medical Device, Medical | $922k–$26M |
|
Wellcome Trust
VC Fund
|
8 | United States, United Kingdom, Germany | Grant, Series C | Biotechnology, Health Care, Pharmaceutical | $1.2M–$90M |
|
Providence Investment Company Limited
VC Fund
|
8 | United Kingdom | Series B, Seed | Biotechnology, Biopharma, Medical | |
|
SyndicateRoom
VC Fund
|
7 | United Kingdom, United States, India | Seed, Equity Crowdfunding | Health Care, Software, Medical | $229k–$1.8M |
|
Calculus Capital
VC Fund
|
6 | United Kingdom, United States, Ireland | Series A, Post-IPO Equity | Biotechnology, Software, Health Care | $2.9M–$9M |
|
M Ventures
VC Fund
|
6 | United States, Switzerland, United Kingdom | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.1M–$67M |
|
Foresight Group
VC Fund
|
6 | United Kingdom, United States, Jersey | Private Equity, Seed | Software, Manufacturing, Health Care | $614k–$136M |
|
Tern
VC Fund
|
6 | United Kingdom, United States | Seed, Series A | Software, Information Technology, Artificial Intelligence | $1.1M–$1.4M |
|
Oxford Investment Consultants LLP
VC Fund
|
6 | United Kingdom | Series A, Seed | Health Care, Software, Biotechnology | $922k–$21M |
|
Kelvin Capital
VC Fund
|
5 | United Kingdom, United States | Seed, Series A | Health Care, Biotechnology, Manufacturing | $139k–$24M |
|
Future Planet Capital
VC Fund
|
5 | United Kingdom, United States | Convertible Note, Seed | Biotechnology, Health Care, Software | $614k–$4.4M |
|
Invest Northern Ireland
VC Fund
|
5 | United Kingdom, United States, Ireland | Grant, Seed | Health Care, Biotechnology, Medical | $37k–$3.7M |
|
Nina Capital
VC Fund
|
5 | United States, United Kingdom, Austria | Seed, Pre-Seed, Series A | Health Care, Artificial Intelligence, Medical | $573k–$21M |
|
VentureFounders
VC Fund
|
5 | United Kingdom, United States | Series A, Seed | Health Care, Software, Medical | $522k–$6.1M |
|
TRICAPITAL
VC Fund
|
5 | United Kingdom, France | Seed, Series B | Biotechnology, Software, Health Care | $172k–$6.4M |
|
Angels 5K
VC Fund
|
5 | United Kingdom | Seed, Angel | Biotechnology, Software, Medical | $74k–$1.2M |
|
Woodford Investment Management
VC Fund
|
5 | United Kingdom, United States, Ireland | Series B, Series A | Biotechnology, Health Care, Medical | $5M–$95M |
|
Co-FundNI
VC Fund
|
5 | United Kingdom, Ireland | Seed, Pre-Seed | Software, Health Care, Information Technology | $369k–$1.7M |
|
QUBIS
VC Fund
|
5 | United Kingdom, United States | Seed, Pre-Seed | Health Care, Medical, Biotechnology | $388k–$3.3M |
|
Syncona Partners LLP
VC Fund
|
5 | United Kingdom, United States, Switzerland | Series A, Series B, Series C | Biotechnology, Therapeutics, Medical | $17M–$123M |
|
Innovate UK
VC Fund
|
5 | United Kingdom, United States, Singapore | Grant, Seed, Pre-Seed | Health Care, Software, Biotechnology | $61k–$3.4M |
|
Praetura Ventures
VC Fund
|
5 | United Kingdom | Seed, Series A | Software, Information Technology, Health Care | $338k–$4.5M |
|
Angels in MedCity
VC Fund
|
5 | United Kingdom, United States | Seed, Angel | Health Care, Biotechnology, Medical | $614k–$774k |
|
SIS Ventures
VC Fund
|
5 | United Kingdom | Seed, Series A | Biotechnology, Health Care, Machine Learning | $764k–$19M |
|
MVM Life Science Partners
VC Fund
|
4 | United States, United Kingdom, Germany | Series B, Series A | Biotechnology, Health Care, Medical | $6.5M–$40M |
|
Cambridge Capital Group
VC Fund
|
4 | United Kingdom, United States | Seed, Series A | Software, Biotechnology, Artificial Intelligence | $528k–$7.8M |
|
Mercia Asset Management
VC Fund
|
4 | United Kingdom, United States | Seed, Series A | Health Care, Software, SaaS | $823k–$2.9M |
|
Spark Ventures
VC Fund
|
4 | United Kingdom, United States, Australia | Series B, Series A | Software, Hardware, Information Technology | $5M–$16M |
|
Northern Powerhouse Investment Fund
VC Fund
|
4 | United Kingdom, Germany, United States | Debt Financing, Seed | Software, Manufacturing, Health Care | $61k–$1.2M |
|
Mercia Asset Management PLC
VC Fund
|
4 | United Kingdom, United States | Series A, Seed | Software, Information Technology, Manufacturing | $369k–$11M |
|
UCLB
VC Fund
|
4 | United Kingdom | Seed, Series A, Pre-Seed | Biotechnology, Medical, Health Care | $945k–$16M |
|
Forbion Capital Partners
VC Fund
|
4 | United States, United Kingdom, The Netherlands | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $4.5M–$115M |
| Access all 743 VC funds in United Kingdom Medical startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 96
- Round size: Seed $246k–$2.9M; Series A $2.7M–$10M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — last raise in 2014
Portfolio highlights
- Machine Discovery — Machine Discovery is a University of Oxford spin-out commercializing new machine learning technology. We leverage proprietary neural network technology to accelerate expensive calculations — and we do it with minimal data and 99.9% fidelity.
- Pencil Biosciences — Next Generation Genome Editing Tool
- Laverock Therapeutics — Laverock Therapeutics is developing a gene silencing platform for the creation of programmable, allogeneic cell therapies.
Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Philippines
Investor stats
- Total investments: 211
- Round size: Seed $860k–$3.7M; Series A $1.5M–$12M; Series B $1.8M–$33M
- Lead/follow: 26% lead, 74% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- RoboK — A Cambridge University spin-out building cost-effective 3D sensing software technology
- Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
- PharmEnable — Designing the next generation of small molecule drugs. Replicating the specificity of biologics in the scalable form of a small molecule.
Deepbridge is a different kind of investment manager. They work closely with financial advisers and investors to design innovative products, ranging from investment in technology growth companies to asset-backed renewable energy projects. They also partner with innovative and committed management teams to help UK based companies realise theirpotential and become successful leading-edge businesses.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, Australia, Singapore
Investor stats
- Total investments: 77
- Round size: Seed $143k–$2.1M; Series A $1.8M–$10M
- Lead/follow: 78% lead, 22% follow
- Last fund: Likely still investing — raised $1.2M in 2022
Portfolio highlights
- Circada — Innovative Circadian lighting reconnects the body clock with nature
- Microplate Dx — Microplate Dx is a developer of diagnostic technology aimed at significantly reducing fatalities caused by drug-resistant infections.Microplate Dx, an award-winning spinout company from the University of Strathclyde in Glasgow, focuses on creating innovative diagnostic solutions to combat the significant global health challenge of antimicrobialresistance. Their technology revolves around the ingenious concept of employing highly sensitive biosensor electrodes, enhanced with miniaturized hydrogel deposits containing various antibiotics tailored to the specific infection being detected. The primary mission of Microplate DX is to proactively prevent and manage the proliferation of antimicrobial resistance on a global scale.
- GenoMe Diagnostics — GenoME Diagnostics - We are developing a blood test for an earlier and more accurate diagnosis of ovarian cancer.GenoME Diagnostics .
Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Grant, Seed
- Geography: United Kingdom, United States, Japan
Investor stats
- Total investments: 193
- Round size: Seed $197k–$2.9M; Grant $92k–$4.1M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- Pneumagen — Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilitiesin glycobiology.
- Microplate Dx — Microplate Dx is a developer of diagnostic technology aimed at significantly reducing fatalities caused by drug-resistant infections.Microplate Dx, an award-winning spinout company from the University of Strathclyde in Glasgow, focuses on creating innovative diagnostic solutions to combat the significant global health challenge of antimicrobialresistance. Their technology revolves around the ingenious concept of employing highly sensitive biosensor electrodes, enhanced with miniaturized hydrogel deposits containing various antibiotics tailored to the specific infection being detected. The primary mission of Microplate DX is to proactively prevent and manage the proliferation of antimicrobial resistance on a global scale.
- Rapscallion Soda — Award Winning, Fresh Fruit, Low Calorie Soft Drinks, Handmade in Scotland. Fresh batches made weekly. Free UK Mainland Delivery. International Shipping. Ginga Ninja | Burnt Lemon | Dry Lime | Scottish Rhubarb Soda | Scottish Strawberry Soda | Cranachan Soda | Blueberry Soda Love soda. Hate hangovers. Drink local.
Oxford Sciences Innovation is the world’s largest university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companiestaking on challenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A
- Geography: United Kingdom, United States, The Netherlands
Investor stats
- Total investments: 123
- Round size: Seed $1M–$6.8M; Series A $3.7M–$34M
- Lead/follow: 41% lead, 59% follow
Portfolio highlights
- Navenio — Navenio is a software technology company that provides location-based services for indoor environments via mobile applications. Its solution provides an improvement on other indoor localization technologies, having the ability to locate people without the need for implementing, managing, or surveying any new building hardware such as beacons orwi-fi. Navenio’s intelligent workforce solution unlocks significant improvements in the efficiency and workflow of staff and teams through automation that is carefully driven from real-world best practice.The company was founded in 2015 and is headquartered in Oxford, England.
- AlveoGene — Welcome to AlveoGene Transforming Rare Respiratory Disease Outcomes Using Inhaled Gene Therapy More information
- Sitryx Therapeutics — Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism.Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK.
Oxford Technology's SEIS fund and EIS fund enable private investors to access high growth technology startup opportunities and support UK innovation. SEIS and EIS tax reliefs offer downside protection, whilst gains can be tax free.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 104
- Round size: Seed $25k–$2M; Series A $737k–$7.4M
- Lead/follow: 7% lead, 93% follow
- Last fund: May invest from a new fund soon — last raise in 2012
Portfolio highlights
- OxCan — Enabling curative cancer treatment through early detection
- Machine Discovery — Machine Discovery is a University of Oxford spin-out commercializing new machine learning technology. We leverage proprietary neural network technology to accelerate expensive calculations — and we do it with minimal data and 99.9% fidelity.
- MitoRx Therapeutics — Developing revolutionary mitochondrial-protective therapeutics which reverse mitochondrial dysfunction to arrest decline in muscular dystrophy and neurodegeneration. MitoRx Therapeutics' first-in-class first-in-target platform has potential to arrest the progression of some of the most challenging diseases.
Our Entrepreneurship team (formerly the Scottish Investment Bank) helps you find sources of finance, engage with funders and secure investment to grow your business.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Series A
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 195
- Round size: Seed $307k–$2.5M; Series A $1.5M–$7.6M
- Lead/follow: 10% lead, 90% follow
- Last fund: May invest from a new fund soon — last raise in 2015
Portfolio highlights
- Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
- IOTech — Discover IOTech Systems, the open edge data platform for developing, deploying, and managing Industrial Edge applications at scale. Find out more here.
- Administrate — Manage 100% of enterprise training operations with configurable training management software, designed to scale with your organization.
Established in 1992. Archangels is the oldest continuously operating business angel syndicate in the World. Investing in IP-rich tech & life sciences companies in Scotland, UK.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 72
- Round size: Seed $123k–$2.7M; Series A $1.5M–$7M
- Lead/follow: 54% lead, 46% follow
Portfolio highlights
- Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
- Cytomos — Cytomos develops and provides integrated, predictive analytics systems for intelligent bioprocessing in biopharma and cell therapy domains.
- Administrate — Manage 100% of enterprise training operations with configurable training management software, designed to scale with your organization.
Mercia Asset Management provides equity and debt to UK businesses with growth ambition. We are your investment partners from scale-up to exit.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Hungary
Investor stats
- Total investments: 119
- Round size: Seed $184k–$1.8M; Series A $1.2M–$21M
- Lead/follow: 69% lead, 31% follow
- Last fund: May invest from a new fund soon — last raise in 2013
Portfolio highlights
- CanSense — CanSense is a developer of an inexpensive and scalable blood test intended for early diagnosis of bowel cancer.
- Workbuzz — Issue employee engagement surveys with WorkBuzz - a fast, simple, and flexible platform with expert consultancy. Try it now!
- Centuro Global — Centuro Global helps you go global.We help startups, scaleups & corporates enter new markets around the world. All your international expansion needs are serviced from one platform, whether you need legal support, tax & accounting, HR, opening a bank account or finding office space, we can assist across the board.Our innovativeplatform, Centuro Connect, contains blueprints on how to do business in over 150 countries, provides live chat advice, and access to local experts around the world. Instead of losing time undertaking Google searches for relevant information and identifying trusted, cost-effective service providers, find all your solutions through Centuro Connect.Come to us for services including; Legal, Immigration, Intellectual Property, Scaling & Expansion, New Market Entry, Tax & Accounting and much more.Receive advice, find service providers, investors and like minded individuals, and seamlessly grow your business.Book a free consultation with us: www.centuroglobal.com
The GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region. The Fund is managed by Catapult Venture Managers ("Catapult Ventures").The Fund is based at Alderley Park, which is well recognised as a site ofnational importance, being the largest life sciences campus of its kind in the UK with more than 500,000 sq. ft. of top-end laboratory and related space and facilities. Until recently, the Park was the R&D headquarters for AstraZeneca.Since 2002, Catapult Ventures has backed a significant number of companies across a broad range of life sciences, including therapeutics (such as Abzena and Oxford BioTherapeutics), medical devices (such as Monica Healthcare and Probe Scientific), contract research organisations (such as R5 Pharmaceuticals and FDAS), diagnostics developers (such as Lumora and Biofortuna), as well as developers of technology used in healthcare applications (such as Oxford Cryosystems and Accutronics). The Fund is the result of a collaboration between Cheshire and Warrington Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, Italy, Germany
Investor stats
- Total investments: 32
- Round size: Seed $61k–$903k
- Lead/follow: 69% lead, 31% follow
Portfolio highlights
- ScubaTx — ScubaTx is a breakthrough organ preservation device organ transplant. The ScubaTx device will leverage world-leading expertise in software design to commercialise a proven but unexploited organ preservation technique, Persufflation. ScubaTx will offer healthcare providers significant net savings, an
- Flynotes — Flynotes is a digital software platform helping dentists deliver personalised patient care
- QV Bioelectronics — Manchester-based start-up QV Bioelectronics is developing innovative electrotherapy devices for the treatment of certain types of brain tumours.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!AlbionVC supports visionary founders with long-term capital and scale-up expertise, and manages c. $1 billion of venture funds, invested in 50+ companies. AlbionVC is the technology investment arm of Albion Capital Group LLP. The technology team invest from seed through to Series B in high growth companies, predominantly in the UK. The team has a focus on B2B software and technology enabled services. AlbionVC %
Show more...Investment focus
- Industry: Software, Health Care, Artificial Intelligence
- Stage:Series A, Seed
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 119
- Round size: Seed $1.8M–$13M; Series A $3.2M–$12M
- Lead/follow: 39% lead, 61% follow
Portfolio highlights
- Umedeor — uMed is a technology platform embedded across a global network of healthcare providers that automates the process of building prospective, protocolized patient registries. This enables sites to participate in dozens of programmes simultaneously without increasing overhead or burden on staff. For life science companies, uMed provides access toregulator quality data, where patients within those datasets can be compliantly re-engaged to support the aims of R&D and post-market teams
- tem. — In a few simple steps we can manage your renewable energy needs forever.
- Ramp Growth — How many users will your mobile game acquire, and how much more will they pour into your virtual economy? Try Ramp to find out.
Development Bank of Wales is formed in 2001 by the Welsh Assembly Government. Development Bank of Wales is an independent company, providing commercial funding to Welsh SMEs. They invests private and public funds, including EU funds.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Seed, Debt Financing
- Geography: United Kingdom, Australia, United States
Investor stats
- Total investments: 149
- Round size: Seed $307k–$1.8M; Debt Financing $12k–$2.8M
- Lead/follow: 58% lead, 42% follow
- Last fund: May invest from a new fund soon — last raise in 2018
Portfolio highlights
- CanSense — CanSense is a developer of an inexpensive and scalable blood test intended for early diagnosis of bowel cancer.
- Stratigens — Talent intelligence software| external people analytics | Diversity, location planning and skills data to inform strategy | Data based decision making
- 2B Enterprising — 2B Enterprising offers an enterprise education program for primary schools that aims to inspire next generation and foster an entrepreneurial mindset.
Newable helps businesses thrive through funding, professional support and premises. Unleashing potential, building resilience & championing growth.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 100
- Round size: Seed $184k–$2.9M; Series A $1.2M–$3.8M
- Lead/follow: 23% lead, 77% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Delta g — Delta g Limited is a quantum technology and gravity gradiometry company. A spin-out from the University of Birmingham our technology has applications in industries as varied as civil engineering, infrastructure, defence, rail, navigation and resource exploration. Experts from science, engineering an
- EarSwitch — Empowering new ways to control and connect with the world through in-ear biometric switch and sensor technology
- RAB Microfluidics — We diagnose early signs of failure in lubricated machinery and prevent equipment failure using our patented microfluidic technology and AI technology.
The team behind Catapult Ventures are among the most experienced venture capital investors in the UK.Their experience spans a range of sectors from healthcare and pharmaceuticals to luxury consumer brands, manufacturing and software, as well as all stages: from start-ups and pre-revenue IP developers to company floatation and billions of poundsin revenue. Their administration team is equally experienced with each member having more than 10 years experience in a venture capital environment.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Pharmaceutical
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Israel
Investor stats
- Total investments: 96
- Round size: Seed $123k–$985k; Series A $1.6M–$26M
- Lead/follow: 26% lead, 74% follow
- Last fund: May invest from a new fund soon — last raise in 2018
Portfolio highlights
- Pickle Robot — We make robots that unload trucks without retrofitting the warehouse
- Urban Machine — Salvaging the past to build the future- Stealth Startup
- Pencil Biosciences — Next Generation Genome Editing Tool
Helping individuals and institutions invest in Venture Capital, Infrastructure and Media companies since 1999.
Show more...Investment focus
- Industry: Software, Mobile, Health Care
- Stage:Seed, Series A
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 133
- Round size: Seed $1.6M–$3.6M; Series A $1.6M–$13M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — last raise in 2015
Portfolio highlights
- Scan.com — Use scan.com to find the best medical imaging centers near you Find an MRI scan, CT scan, X-ray Scan, or other diagnostic imaging scan with scan.com.
- HelloSelf — The UK's Trusted Online Private Clinical Therapy Service
- Legislate — Legislate is an easy-to-use contract management platform which provides a suite of customisable contracts for businesses and landlords.
Cambridge Innovation Capital backs life sciences and technology companies with an affiliation to Cambridge, Europe’s capital for innovation. As a preferred investor for the University of Cambridge, they have unparalleled access to investment opportunities in the ecosystem.Since our inception in 2013, they have raised £275 million to invest indisruptive, deep-tech businesses in sectors including, but not limited to, artificial intelligence, the internet of things, quantum technologies, autonomous systems, therapeutics, medtech/diagnostics, digital health, and genomics/proteomics.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Seed
- Geography: United Kingdom, United States, Ireland
Investor stats
- Total investments: 81
- Round size: Seed $614k–$13M; Series A $1.8M–$39M; Series B $6.5M–$61M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Riverlane — Riverlane's mission is to make quantum computing useful far sooner than previously imaginable, starting an era of human progress as significant as the industrial and digital revolutions.
- Mosaic Therapeutics — Mosaic Therapeutics is reshaping the interface of computational and experimental medicine to power new medicines for patients.
- Complement Therapeutics — Turning powerful new Complement System insights into innovative treatments Developing the next generation of complement medicines [chevron-down] Turning powerful new Complement System insights into innovative treatments Developing the next generation of complement medicines [chevron-down] Geographic atrophy (late dry age-related macular degeneration) is a chronic eye condition that affects millions - and for which there is
Northstar Ventures is a venture capital firm investing in innovative solutions to help solve the most pressing societal issues we have today. Our ticket sizes range from £100k to £500k into early stage tech companies. We provide added value in leveraging our network of university partners, funders, non-executive directors and talent to supporteach investment.
Show more...Investment focus
- Industry: Software, E-Commerce, Internet
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Estonia
Investor stats
- Total investments: 153
- Round size: Seed $37k–$1.2M; Series A $276k–$8.8M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — last raise in 2018
Portfolio highlights
- IOTech — Discover IOTech Systems, the open edge data platform for developing, deploying, and managing Industrial Edge applications at scale. Find out more here.
- MarraBio — MarraBio Ltd. is a spin out company from Newcastle University using engineered bacterial protein polymers to provide bioactivity to cells at the industrial scale in the cultivated meat sector and beyond.
- Peek Home — Peek Home provides sketch plans, prices and planning advice for people who are puzzled by the process of creating their perfect home. All we need is your house number & postcode - no home visit needed.
IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Therapeutics
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Australia
Investor stats
- Total investments: 157
- Round size: Seed $369k–$6.4M; Series A $1.8M–$17M; Series B $7.4M–$61M
- Lead/follow: 24% lead, 76% follow
- Last fund: May invest from a new fund soon — last raise in 2014
Portfolio highlights
- AccelerComm — Our patented, market-leading IP solutions for 4G and 5G are configurable for quick, high-performance implementations across a wide range of applications.
- Deep Render — Deep Render Ltd. is a spin-out from the Department of Computing at Imperial College London. We are a London based AI start-up that is developing the next generation of media compression algorithms. Our proprietary and patented technology is at the forefront of machine learning research. Furthermore, our Biological Image Compression results arestate-of-the-art, providing at least a 50% efficiency gain over the previous standards
- Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
We bring bold ideas to life to change the world for good.
Show more...Investment focus
- Industry: Biotechnology, Medical Device, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 72
- Round size: Seed $922k–$2.2M; Series A $1.5M–$26M
- Lead/follow: 10% lead, 90% follow
- Last fund: May invest from a new fund soon — raised $31M in 2014
Portfolio highlights
- Citymart — Citymart powers cities to deliver services that work. Following best practices developed with leading cities around the world, Citymart connects cities and revolutionizes the way cities frame needs, complete procurements, and improve service delivery. Over 100 cities in 35 countries have adopted Citymart tools and methods to-date.
- Featurespace — Featurespace™ is the world leader in Enterprise Financial Crime prevention for fraud and Anti-Money Laundering. Featurespace invented Adaptive Behavioral Analytics and Automated Deep Behavioral Networks, both of which are available through the ARIC™ platform, a real-time machine learning software that risk scores events in more than 180 countriesto prevent fraud and financial crime.ARIC™ Risk Hub uses advanced, explainable anomaly detection to enable financial institutions to automatically identify risk, catch new fraud attacks and identify suspicious activity in real-time. More than 30 major global financial institutions are using ARIC to protect their business and their customers. Publicly announced customers include HSBC, TSYS, Worldpay, NatWest, Contis, Danske Bank, ClearBank, Akbank and Permanent TSB.
- Radio Physics Solutions — Download Lagu MP3 Gratis. Download Lagu Gratis Terbaru 2023, Situs Download Lagu Mp3 Gratis, Download Lagu dari YouTube, Gudang Lagu Indonesia, Barat Terbaik, Cepat dan Mudah.
Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science. It was founded in 1936 and headquartered in London, England.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Grant, Series C
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 109
- Round size: Grant $1.2M–$6.8M; Series C $10M–$90M
- Lead/follow: 36% lead, 64% follow
- Last fund: May invest from a new fund soon — last raise in 2018
Portfolio highlights
- Vaxxas — Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia.
- DataDotOrg — data.org brings together philanthropy, technology, academia, and social impact organizations to build the field of data science for social impact.
- Feinstein Institute for Medical Research — Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes ofbehavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Providence Investment Company
Show more...Investment focus
- Industry: Biotechnology, Biopharma, Medical
- Stage:Series B, Seed
- Geography: United Kingdom
Investor stats
- Total investments: 12
- Lead/follow: no public data
Portfolio highlights
- evonetix — evonetix is a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniqueswe are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines.
- DefiniGEN — Generate metabolic disease phenotypes in primary-like human cells using the best-in-class human iPSC differentiation platform. Find out more here!
- CellCentric — CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.
SyndicateRoom is fintech company made up of data-scientists, investment professionals, software developers and marketers with one mission: to be an early investor in every British startup success story.To do this – and make fund investors money – we don’t try to spot the next Big Thing.Instead, we apply a data-driven model to portfolioconstruction; a repeatable process designed to maximise returns and minimise risk for fund investors. As such, we build startup portfolios that don’t attempt to predict the future; they work to stack the odds in investors’ favour.Our fund, Access EIS, aims to build investors a diversified portfolio of 50+ companies by co‑investing exclusively with some of the UK’s best-performing angel investors.
Show more...Investment focus
- Industry: Health Care, Software, Medical
- Stage:Seed, Equity Crowdfunding
- Geography: United Kingdom, United States, India
Investor stats
- Total investments: 109
- Round size: Seed $240k–$1.8M; Equity Crowdfunding $229k–$1.5M
- Lead/follow: 10% lead, 90% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Connectd — Online platform underpinned by smart matching technology directly connecting the UK’s leading Founders, Investors & NAMs.
- Five Alarm Bio — Five Alarm Bio is a drug discovery company. Five Alarm intends to use discoveries to provide secure and efficient remedies for a variety of age-related illnesses and limitations. Five Alarm Bio is creating a small molecule strategy to strengthen the body's defense against aging.
- Pencil Biosciences — Next Generation Genome Editing Tool
At Calculus Capital they are specialists in creating and managing tax efficient private equity funds for the individual. Funds that are ideal for today's market - offering generous tax benefits, and significant growth potential within a sensible risk profile.They look to make £2-5 million investments in established companies with provenmanagement teams and a successful product or service. Their entrepreneurial flair, combined with their experience and sound commercial judgement has resulted in a diversified investment portfolio and an impressive track record. In June 2013 Calculus Capital was top ranked in the prestigious Martin Churchill Tax Efficient Review for the 6th year in a row. The Government has recently shown its support for EIS funds, by maintaining the five generous tax benefits and widening the scope of EIS investments. These changes benefit Calculus Capital's rigorous and proven strategy. As a result they are experiencing their strongest pipeline of prospective investments yet.
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Series A, Post-IPO Equity
- Geography: United Kingdom, United States, Ireland
Investor stats
- Total investments: 59
- Round size: Series A $3.1M–$6.5M; Post-IPO Equity $2.9M–$9M
- Lead/follow: 68% lead, 32% follow
Portfolio highlights
- Wazoku — Wazoku - Where Innovation Works Wazoku
- Arctic Shores — Unearth meaningful, job-relevant insights through our candidate assessments. A new type of behaviour based assessment that's powered by neuroscience.
- Laverock Therapeutics — Laverock Therapeutics is developing a gene silencing platform for the creation of programmable, allogeneic cell therapies.
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 119
- Round size: Seed $2.1M–$18M; Series A $6M–$42M; Series B $9.5M–$67M
- Lead/follow: 39% lead, 61% follow
Portfolio highlights
- CellFE — CellFE is a company developing a microfluidics based device to deliver gene-editing molecules. CellFE developed microfluidic device and process that can efficiently deliver gene-editing molecules into the human cells.
- BeeOLED — BeeOLED’s technology enables OLED displays with significantly improved efficiency, brightness and operational stability at lower overall costs due to a less complex device structure.
- Lightcast Discovery — Flexible control over droplet number, occupancy, location and movement. Enabling efficient, multi-step workflows with unprecedented flexibility.
Foresight Group is a listed infrastructure and private equity investment manager which has been managing funds on behalf of institutions and retail clients for more than 35 years. Foresight has over £7.2 billion of assets under management across a number of funds on behalf of some of the world’s largest institutional investors, family offices,private and high net-worth individuals and retail investors. Foresight's investment strategies are underpinned by a strong environmental, social & governance (“ESG”) focus, which increasingly meets the demands of today’s investors and ensures we are consistently working towards creating a sustainable legacy for future generations.
Show more...Investment focus
- Industry: Software, Manufacturing, Health Care
- Stage:Private Equity, Seed
- Geography: United Kingdom, United States, Jersey
Investor stats
- Total investments: 137
- Round size: Seed $614k–$14M; Private Equity $2M–$136M
- Lead/follow: 66% lead, 34% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Previsico — Previsico is a spinOut company from Loughborough University specialising in modelling flooding in real-time, using weather predictions to make street-level flood nowcasts and forecasts. The company's mission is to be the leading global provider of cutting-edge flood prediction that saves lives and livelihoods.Its FloodMap Live producesround the clock street-level flood risk predictions and analytics. Uniquely, these are continuously modelled and updated using a combination of different weather forecasts. This allows the company to map the likelihood of short and long-term surface water events in real-time to the street level.
- Looper Insights — Looper Insights - Optimizing Content and App Placement Across Connected TV Devices. The market leader in analytics on Connected TV devices.
- We Are Fulfilment — We Are Fulfillment is an e-commerce company that provides warehousing and management services.
Looking for an IoT investor for your start up or early stage company? Tern PLC is a venture capitalist working alongside ambitious entrepreneurs in the Internet of Things (IoT) space to deliver strategic IoT investment to grow your company.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 20
- Round size: Seed $1.1M–$1.4M
- Lead/follow: 30% lead, 70% follow
Portfolio highlights
- Konektio — With over 20+ years of industrial IoT experience - Konektio's condition-based and energy-monitoring solutions keep your machines running.
- FundamentalVR — Implement a customized, flexible, and cost-effective training solution to accelerate the rollout of your medical device, surgical robotic system, or product.
- Talking Medicines — Data tech innovator Talking Medicines, based in Glasgow and London, uses advanced AI and ML to provide pharmaceutical companies with real-time data intelligence. The company uses a collection of AI, ML and NLP tech tools to capture and structure the voice of the patient from real world conversations and behaviours at home. Through mapping thepatient voice from social media and connected devices to regulated medicine information, the company is able to build data points to deliver trends and patterns of patient sentiment across medicines. This intelligence embraces regulatory compliance enabling marketing in pharmaceutical companies to measure patient confidence by medicine and in turn action the levers for share growth.
xford Investment Consultants LLP ("OIC") advises Thompson Taraz, the Investment Manager of Oxford Technology and Innovations EIS Fund ("OTIF"). OIC is an Appointed Representative of Stoneware Captial LLP, which is authorized and regulated by the Financial Conduct Authority in the United Kingdom.The focus of OIC research ison University of Oxford spin out companies.Over the last fifteen years Oxford has produced a string of world-class spin-out companies. It is our belief that the next generation of world-class Oxford businesses is just waiting to be discovered.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Series A, Seed
- Geography: United Kingdom
Investor stats
- Total investments: 23
- Round size: Seed $922k–$7.1M; Series A $11M–$21M
- Lead/follow: 9% lead, 91% follow
- Last fund: May invest from a new fund soon — last raise in 2012
Portfolio highlights
- Diffblue — Diffblue Generative AI for Code helps you shift left by autonomously writing full suites of Java unit regression tests so you can catch errors faster and earlier in your pipeline
- Living Optics — Living Optics is commercializing next generation imaging technology which leverages a compact camera system based on breakthroughs in hardware design and software processing.
- Caristo Diagnostics — Coronary Artery Inflammation causes heart attacks. We detect and measure coronary inflammation and plaque on CCTA with CaRi-Heart technology
We invest venture capital in to globally ambitious companies which have the potential to deliver a significant return to our investors
Show more...Investment focus
- Industry: Health Care, Biotechnology, Manufacturing
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 72
- Round size: Seed $139k–$1.1M; Series A $1.6M–$24M
- Lead/follow: 49% lead, 51% follow
Portfolio highlights
- novosound — Novosound is an award winning Scottish sensors company utilising thin-film processes to eliminate conventional limitations in ultrasound sensors.
- Snappy Shopper — Order your favourite products from your local convenience store, for delivery from as little as 30 minutes with Snappy Shopper. Your every day essentials are only a click away - order your grocery delivery online or through our app.
- Sofant Technologies — Sofant is developing a low cost RF MEMS technology that solves power consumption and heat problems in high frequency phased array antenna systems.
Brilliant Ideas. Brilliant People. Brilliant Minds.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Convertible Note, Seed
- Geography: United Kingdom, United States
Investor stats
- Total investments: 113
- Round size: Seed $614k–$4.4M
- Lead/follow: 3% lead, 97% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Captura — Captura mission is globally scalable carbon capture to support a sustainable future for the climate.
- Regent — We build all-electric, passenger-carrying, wing-in-ground-effect vehicles to service coastal routes with technology available today.
- Queen of Raw — Queen of Raw is a global marketplace with AI-powered supply chain software to eliminate and monetize textile waste, tracking and analyzing data to keep unused raw materials out of landfills and turn pollution into profit. An integrated dashboard allows its customers to visualize savings to their bottom- and top-lines as well as to the environmentby the actions they take across the Queen of Raw platform. Queen of Raw has helped 400,000+ users save millions of dollars—and more than a billion gallons of water.Queen of Raw is powered by mmx (http://www.materiamx.com/).
Invest Northern Ireland is Northern Ireland's economic development agency. Their overall goal is to help create wealth for the benefit of the whole community by strengthening the economy and helping it grow.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Grant, Seed
- Geography: United Kingdom, United States, Ireland
Investor stats
- Total investments: 32
- Round size: Seed $37k–$614k; Grant $276k–$3.7M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- TruCorp — TruCorp provide professional medical training equipment including realistic & lifelike intubation manikins & airway trainers. Request a free demo.
- Signum Surgical — Founded in 2014 by Eoin Bambury and Moshe Zilversmit, Signum Surgical is a medtech platform striving to develop technology that could cure perianal fistula. Bambury and Zilversmit, who met on the BioInnovate Ireland programme at NUI Galway, recognised a lack of innovation surrounding the treatment of perianal fistulas (small tunnels that developbetween the end of the bowel and the skin near the anus). The device developed by Signum Surgical is implanted post-surgery to prevent reinfection and to allow a faster healing process.
- CV6 Therapeutics — CV6 Therapeutics is a drug development company focused on the discovery, development and commercialization of novel therapies for the treatment of human diseases.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!We deploy early stage capital to fuel the growth of need-driven health technology companies.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Medical
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, United Kingdom, Austria
Investor stats
- Total investments: 58
- Round size: Seed $1.2M–$6M; Pre-Seed $573k–$964k; Series A $5M–$21M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- basys.ai — Basys.ai automates the process of prior authorization and utilization management to improve costs and timeliness for health plans/payers using an AI-based platform. The proprietary platform automates the process of encoding/digitizing the payer policies using machine learning, thus reducing the piloting timeline by up to 9 months.
- Lillian Care — Lillian is building a nationwide network of health facilities in Germany.
- ALFIE — AI software platform that provides consistent and automated measurements from radiographic images used to assess spinal disorders.
Volution is a UK based Venture Capital firm. We back ambitious Fintech and SaaS businesses, ready to accelerate their growth to Series B and beyond.
Show more...Investment focus
- Industry: Health Care, Software, Medical
- Stage:Series A, Seed
- Geography: United Kingdom, United States
Investor stats
- Total investments: 48
- Round size: Seed $522k–$1.2M; Series A $603k–$6.1M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- Zopa — Zopa is a P2P money lending service that allows lenders and borrowers to deal directly with one another, cutting out the banks who act as middlemen. It works in the following way: the company first categorizes borrower credit grades with an A*, A, B, C, or Y rating; then lenders make offers that vary by money amount and time period for persons witha certain credit grade, and borrowers can then agree the aggregate offered rate.Zopa takes on such responsibilities as distributing money between parties, completing the legal paperwork, performing borrower identity/credit checks, and employing a collections agency that chases missed payments for the lender.Zopa also mitigates risk for lenders by enforcing monthly direct debit repayment, making borrowers sign a legal contract, and allowing lenders to lend small chunks of money to individual borrowers (i.e. someone lending £1000 would have their money spread across say, 100 borrowers).The company itself makes money by charging a fixed fee for borrowers and a 1% annual fee for lenders.Zopa has received public acclaim as well, having been awarded CNET Technology Awards' 2006 Internet Innovation of the Year, the 2007 Webby Award for Best Banking/Bill-Paying Website, the 2008 Webby Award for Financial Services, the Banker 2007 Award for Best Internet Project, and Moneywise 2009 Awards for Best Customer Service and Best Personal Loan.One of the three initial members of the UK's Peer-to-Peer Finance Association, together with FundingCircle and RateSetter. Other P2P lending services include
- DeadHappy — Life's too short to shop around for life insurance. Say hello to DeadHappy, a brand new type of life insurance that's quick, easy and flexible.
- Lightpoint Medical — Lightpoint is developing miniaturized imaging and sensing tools for advanced robot-assisted cancer surgery.
The TRICAPITAL Syndicate is a business angel cohort of entrepreneurs, CEOs and business leaders who have founded, funded and built companies
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Seed, Series B
- Geography: United Kingdom, France
Investor stats
- Total investments: 47
- Round size: Seed $246k–$1.2M; Series B $172k–$6.4M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- ŌGI Bio — Offering an affordable route to automating routine microbial culturing with a unique, modular, retrofittable device
- Carcinotech — Carcinotech is a MedTech company manufacturing 3D printed mini tumours developed from patient-specific cancer stem cells, primary cells and established cell lines.
- Heero Technologies — Heero Technologies, the leading independent energy platform for making net zero homes a reality
Southern Angel Investors Club, combining Surrey investors Club & Angels 5K, are entrepreneurs who understand what new businesses need.
Show more...Investment focus
- Industry: Biotechnology, Software, Medical
- Stage:Seed, Angel
- Geography: United Kingdom
Investor stats
- Total investments: 26
- Round size: Seed $74k–$1.2M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Celixir — Celixir is a developer of regenerative medicines created to change the lives of patients in need. The company's medicines consists of iMP cells, platelet lysate and PML cells to treat patients with ischaemic heart disease, injured tendons near the surface of the skin and mild to moderate heart failure respectively, enabling medical researchersto discover breakthrough medicines that aim to change the standard of medical care for patients.
- Novastone Media Ltd. — With its unique asymmetric technology, novastone puts you directly where your clients want to talk to you.
- Geektastic — Geektastic guarantees hiring teams only meet high calibre candidates. Our technical code challenges quickly identify the most talented software engineers.
Woodford Investment Management is a privately owned investment firm manages equity mutual funds. At Woodford, they don’t want to be just another fund management company. They want to create something different and better for their investors and they feel strongly that existing and potential clients are entitled to understand what they are doingwith their money.As investors, they are active, engaged, long-term, disciplined, diligent and focused. That’s a lot of things to say about their selves but each word is important in helping you to understand how they manage money – they will explain in more detail as they move along.Their investment approach and process are focused on value discovery, not price discovery. They believe that financial markets are inherently inefficient and that, through disciplined and diligent analysis, they can identify investment opportunities where market prices do not reflect long-term fundamental value. By exploiting this pervasive market characteristic, they believe they can create real long-term value for their investors.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A
- Geography: United Kingdom, United States, Ireland
Investor stats
- Total investments: 62
- Round size: Series A $5M–$95M; Series B $9.8M–$53M
- Lead/follow: 45% lead, 55% follow
- Last fund: May invest from a new fund soon — last raise in 2015
Portfolio highlights
- Inivata — Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis to improve testing and treatment for oncologists and their patients.Unlike conventional invasive biopsies, Inivata detects and analyses genomic material from a cancer patient’s cell-free, circulating tumor DNA (ctDNA) which can be collectedthrough a simple blood sample. This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored, and treated.
- Revolut — Open a free account in minutes right from your phone, and make your money go further
- Atom Bank — Savings accounts, a range of mortgages & business loans, you'll find it all with Atom bank. App-based and designed to be hassle-free. Download the app today.
Through Co-Fund NI £12.5million will be made available to invest alongside business angels and business angel syndicates (hereafter referred to as "private investors" or "syndicates") into eligible SME's based in Northern Ireland. When matched 45% public with 55% private investors on a deal-by-deal basis this will give anoverall "fund" size of £28m.This initiative is provided by Invest Northern Ireland and part-financed by the European Regional Development Fund under the Invest for Growth and Jobs Programme 2014-2020.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Pre-Seed
- Geography: United Kingdom, Ireland
Investor stats
- Total investments: 40
- Round size: Seed $369k–$1.7M; Pre-Seed $369k–$369k
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Kinsetsu — Organisations are continually challenged to find better ways to manage processes. Traditional approaches are being pushed to their limits.
- CV6 Therapeutics — CV6 Therapeutics is a drug development company focused on the discovery, development and commercialization of novel therapies for the treatment of human diseases.
- GenoMe Diagnostics — GenoME Diagnostics - We are developing a blood test for an earlier and more accurate diagnosis of ovarian cancer.GenoME Diagnostics .
QUBIS Ltd was established in 1984 by The Queen's University of Belfast to commercialise the University's research and development activities through the formation of 'spin-out' businesses. Qubis Ltd is an investment vehicle, holding company which takes an equity holding in a new spin-out venture in return for an investment ofcash and/or Intellectual Property. Qubis Ltd 'pulls through' appropriate R & D from the laboratory into the commercial market place.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Seed, Pre-Seed
- Geography: United Kingdom, United States
Investor stats
- Total investments: 22
- Round size: Seed $388k–$3.3M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- VascVersa — VascVersa is a new cell therapy company based in Northern Ireland. At VascVersa we are developing medicines to create new blood vessels, repair tissue and promote healing.
- CV6 Therapeutics — CV6 Therapeutics is a drug development company focused on the discovery, development and commercialization of novel therapies for the treatment of human diseases.
- GenoMe Diagnostics — GenoME Diagnostics - We are developing a blood test for an earlier and more accurate diagnosis of ovarian cancer.GenoME Diagnostics .
Syncona is a FTSE250 company focused on founding, building and funding healthcare companies to deliver transformational treatments to patients in areas of high unmet need.
Show more...Investment focus
- Industry: Biotechnology, Therapeutics, Medical
- Stage:Series A, Series B, Series C
- Geography: United Kingdom, United States, Switzerland
Investor stats
- Total investments: 37
- Round size: Series A $17M–$110M; Series B $22M–$123M; Series C $40M–$80M
- Lead/follow: 59% lead, 41% follow
Portfolio highlights
- Beacon Therapeutics — Beacon Therapeutics is an ophthalmic gene therapy company that restores and improves vision and rare retinal diseases that result in blindness.
- Mosaic Therapeutics — Mosaic Therapeutics is reshaping the interface of computational and experimental medicine to power new medicines for patients.
- SwanBio Therapeutics — SwanBio Therapeutics is a gene therapy company that aims to bring life-changing treatments to people with devastating, genetically defined neurological conditions.
Innovate UK is part of the UK Research and Innovation .
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Grant, Seed, Pre-Seed
- Geography: United Kingdom, United States, Singapore
Investor stats
- Total investments: 288
- Round size: Seed $283k–$3.4M; Grant $61k–$2.5M; Pre-Seed $123k–$922k
- Lead/follow: 79% lead, 21% follow
Portfolio highlights
- FlexSea — FlexSea develops novel biomaterials derived from renewable marine resources to replace current primary plastic packaging.
- Concretene — Concretene is a concrete alternative that is designed to provide a viable CO2 reduction technology in the construction industry for cementitious products. It is developed by Nationwide Engineering Research and Development (NERD) with the Graphene Engineering Innovation Centre (GEIC).
- Pathios Therapeutics — Pioneering a novel macrophage conditioning approach to delivering breakthrough cancer therapies
Praetura Ventures has been supporting entrepreneurs with more than money since 2011. Click to find out more about how we can help businesses and investors.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Series A
- Geography: United Kingdom
Investor stats
- Total investments: 91
- Round size: Seed $338k–$4.1M; Series A $1.2M–$4.5M
- Lead/follow: 78% lead, 22% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Covatic — We help media companies deliver private-by-design, addressable advertising and marketing without exposing personal data.
- Decently — Decently provides the world a better place by developing advanced digital products. Decently mission is to improve lives through innovative digital product.
- Percayso Inform — Percayso provides insurers with access to a wide range of data sources, allowing them to form a more comprehensive view of their customers.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Angels in MedCity is a partnership between MedCity, London Business Angels and Angels4LifeSciences. The programme aims to introduce new people to investing and investing in the healthcare/life sciences sector via investor workshops and introduce business angels to investment opportunities from highly-selected and trained companies.With aparticular focus on drug therapies, digital health and medical device technologies, Angels in MedCity brings potential investors together with life sciences experts in a programme aimed at both people who are new to investing and experienced investors who have little or no experience in the life sciences sector. The aim is to build investor understanding in the life sciences sector and support life sciences companies to gain funding to commercialise their ideas.Angels in MedCity has created a community of investors supported through a programme of investor workshops. Using case studies and tips from experienced investors in the field, the workshops explain how to identify and structure a good deal in the life sciences sector, as well as provide expert advice on tax breaks and legal issues.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Angel
- Geography: United Kingdom, United States
Investor stats
- Total investments: 18
- Round size: Seed $614k–$774k
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- Atelerix — The Atelerix technology provides an innovative solution for storing and transporting cells and tissues at room temperature.
- Clustermarket — The intuitive lab management system for all academic research facilities and industrial laboratories that need to efficiently manage equipment bookings.
- DynamX Medical — DynamX Medical has developed a reliable and inexpensive precancer screening system for rapid tissue biopsy analysis that can be operated point-of-care by nurses.
SIS Ventures has been created with the overall aim of supporting and growing high impact organisations through access to mission-aligned investment. SIS Ventures has a goal of becoming the go to investor and partner for social entrepreneurs. The fund will offer conventional financial returns alongside social and/or environmental returns byinvesting either equity or debt into purpose driven companies.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Machine Learning
- Stage:Seed, Series A
- Geography: United Kingdom
Investor stats
- Total investments: 17
- Round size: Seed $764k–$2.9M; Series A $2.7M–$19M
- Lead/follow: 6% lead, 94% follow
- Last fund: May invest from a new fund soon — last raise in 2018
Portfolio highlights
- Dxcover — Dxcover are a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other diseases to improve survival and quality of life.
- MiAlgae — MiAlgae is a new-age microalgal production company that aims to revolutionize the £340 billion global livestock feed industry by producing microalgal products – through the remediation of wastewater – as nutrient supplements for fishmeal in livestock feeds. Their microalgal products are high in omegas and proteins, both of which are required forthe production of many livestock feeds, especially in the aquaculture sector.Their production methodology uses circular economy to reduce the operating costs involved in the production of microalgae and as such allows them to compete with other supplements currently on the market.
- Microplate Dx — Microplate Dx is a developer of diagnostic technology aimed at significantly reducing fatalities caused by drug-resistant infections.Microplate Dx, an award-winning spinout company from the University of Strathclyde in Glasgow, focuses on creating innovative diagnostic solutions to combat the significant global health challenge of antimicrobialresistance. Their technology revolves around the ingenious concept of employing highly sensitive biosensor electrodes, enhanced with miniaturized hydrogel deposits containing various antibiotics tailored to the specific infection being detected. The primary mission of Microplate DX is to proactively prevent and manage the proliferation of antimicrobial resistance on a global scale.
MVM invests in innovative healthcare companies. Our active portfolio companies are transforming the delivery of healthcare by enabling higher quality, cost-effective care in large, global markets.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 61
- Round size: Series A $6.5M–$36M; Series B $6.5M–$40M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Ossio — OSSIO is an orthopedic fixation company committed to transforming the orthopedic experience for patients, physicians, and payors. Their vision is to provide the first credible replacement to metal implants in the $10B+ orthopedic fixation market (screws, pins, plates) with an Intelligent Bone Regeneration Technology. OSSIOfiber represents abreakthrough material platform for orthopedic and podiatric surgeons who seek a more biologically friendly way to restore patient stability and mobility with nothing permanent left behind.Founded in 2014, OSSIO began as the culmination of years of biomechanical research and a vision for the possibility of better bone healing. The technological basis of OSSIOfiber™ was developed and would lay the groundwork for ushering in a new breakthrough category of non-permanent fixation, “Bio-Integratives” hardware that has both desired strength AND bio-friendliness. Hardware that has the mechanical strength for easy insertion and secure fixation, while enabling the body to regrow bone, incorporating and replacing the implant (without the adverse inflammation and weakness often seen in “bio-resorbables and other “bio-composites”), has remained elusive to the industry until now.
- Nalu Medical — Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people.The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS)and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California.
- Neurolens — 2/3 of patients experience the symptoms of eye misalignment, but relief is in sight with Neurolens using the NMD2 and Neurolenses with Contoured Prism.
Cambridge Capital Group (CCG) is a leading business angel group of 70+ investors who have been investing in hi-tech businesses for more than a decade. CCG was formed in the Autumn of 2000 and has been backing tech start-ups in the region ever since. Their members have invested several millions of pounds into more than 30 live portfolio companies inthe Cambridge technology cluster. Membership is an application process, normally following introductions by existing members.Their partner networks are Anglia Capital Group and CCG International, both of which benefit from deal flow developed in Cambridge, Europe's leading hi-tech cluster.
Show more...Investment focus
- Industry: Software, Biotechnology, Artificial Intelligence
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 40
- Round size: Seed $528k–$1.8M; Series A $1.2M–$7.8M
- Lead/follow: 10% lead, 90% follow
- Last fund: May invest from a new fund soon — last raise in 2016
Portfolio highlights
- Qualus — Bringing sustainable leather solutions to leather tanneries and brands. Qualus enables you to deliver environmentally friendly luxury leather production.
- Cytochroma — Cytochroma manufacture genetically diverse stem cell-derived models to predict the safety and effect of drugs in a global population. Cytochroma’s automated cell manufacture, physiologically relevant models and rapid screening platform makes preclinical testing faster, safer and smarter.
- Cambridge GaN Devices — Cambridge GaN Devices develops transistors designed to bring widespread adoption of GaN technology in consumer electronics.
Mercia Asset Management provides equity and debt to UK businesses with growth ambition. We are your investment partners from scale-up to exit.
Show more...Investment focus
- Industry: Health Care, Software, SaaS
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 17
- Round size: Seed $823k–$2.9M
- Lead/follow: 41% lead, 59% follow
- Last fund: May invest from a new fund soon — last raise in 2011
Portfolio highlights
- Cloud8 — At Cloud8 It provide an intuitive cloud platform to corporate advisors. It improving the employee experience through affordable digital benefits, excellent support, reporting and communications – something which has previously been out of reach for SME clients.
- Citizenme — Real people. Deeper insights. Better business. The only fully-functional zero-party data platform. Built by experts. Powered by citizens.
- Sense Biodetection — Sense Biodetection Limited is a molecular diagnostics company focused on improving healthcare decisions and processes by developing novel, user-centred, handheld tests in the fields of infections and oncology.
SPARK Ventures, formerly NewMediaSpark, is an early-stage venture capital investor in Europe, providing equity investment to high growth technology, media and healthcare companies in the UK and Europe. SPARK Ventures has been investing in early-stage businesses for 12 years and has a wealth of expertise in backing and developing companiesfrom start-up through to eventual trade sale or IPO.
Show more...Investment focus
- Industry: Software, Hardware, Information Technology
- Stage:Series B, Series A
- Geography: United Kingdom, United States, Australia
Investor stats
- Total investments: 20
- Round size: Series A $7M–$14M; Series B $5M–$16M
- Lead/follow: 15% lead, 85% follow
Portfolio highlights
- Haemostatix — Based at BioCity, Nottingham, UK, Haemostatix Ltd was co-founded in 2003 by Sarah Middleton and Professor Alison Goodall as a spin-out from the University of Leicester. The Company was established to commercialise a new technology platform based upon a specific peptide sequence that binds to fibrinogen – a protein essential to the formation ofclots. The peptide is coupled to different forms of solid support or soluble carriers to create both topical and systemic haemostats. This new technology platform is the basis of a pipeline of first-in-class products to treat various forms of bleeding in surgery, trauma and in leukaemic patients.
- Simba Sleep — One Mattress. Five Layers of Comfort. Tailored to Suit All. Bringing together experience & technology so that your mattress gives you the best night's sleep.
- Oxford Immunotec — Oxford Immunotec is a medical diagnostics company developing novel new tests for various diseases based on its innovative, patented T cell measurement technology. The company's first product is a TB test that diagnoses latent TB infection ( LTBI ) and TB disease. T-SPOT®.TB is an interferon gamma release assay ( IGRA ) which are designed toreplace the century old Mantoux skin test ( TST ).
Northern Powerhouse Investment Fund (NPIF) is an initiative launched by the government-owned British Business Bank.It is a key part of the government’s ‘Northern Powerhouse’ vision, which aims to end the historic North / South divide and create economic prosperity in the North of England on par with London and the South East.Thegovernment firmly believes that SMEs form the foundation of the region’s future growth. NPIF therefore aims to nurture regional entrepreneurship by providing investment and support for small and medium businesses between 2016 and 2021. NPIF's funding will support new and growing SMEs, create jobs and encourage and attract additional private sector investment.
Show more...Investment focus
- Industry: Software, Manufacturing, Health Care
- Stage:Debt Financing, Seed
- Geography: United Kingdom, Germany, United States
Investor stats
- Total investments: 75
- Round size: Seed $61k–$1.2M; Debt Financing $123k–$707k
- Lead/follow: 43% lead, 57% follow
- Last fund: May invest from a new fund soon — last raise in 2017
Portfolio highlights
- Konektio — With over 20+ years of industrial IoT experience - Konektio's condition-based and energy-monitoring solutions keep your machines running.
- AssetCool — AssetCool is a thermal metaphotonics company. It produces photonic coatings and materials that enhance the functionality of electrical networks.
- Biorelate — Biorelate provides biomedical research services. It engages in the research of biomarkers for the diagnosis of prostate cancer; target validation; and new drug development services. Daniel Jamison founded Biorelate in 2014. It has its headquarters in Oldham in the United Kingdom.
Mercia Asset Management providing equity and debt to regional businesses with growth ambition. We are your capital partners from scale-up to exit.
Show more...Investment focus
- Industry: Software, Information Technology, Manufacturing
- Stage:Series A, Seed
- Geography: United Kingdom, United States
Investor stats
- Total investments: 74
- Round size: Seed $369k–$2.7M; Series A $1.2M–$11M
- Lead/follow: 66% lead, 34% follow
- Last fund: May invest from a new fund soon — raised $33M in 2018
Portfolio highlights
- Camena Bioscience — Camena Bioscience is a synthetic biology company that develops tools to engineer new synthetic biology applications. It has engineered new nucleic acid synthesis technology which improves the quality and speed of synthesis. Its multi-enzymatic technology takes one approach to DNA, RNA, and XNA synthesis, offering increased accuracy over existingPhosphoramidite synthesis technology.Camena Bioscience was founded in 2016 and is headquartered in Cambridge.
- Nova Pangaea Technologies (NPT) — NPT is a cleantech company that has developed a revolutionary process technology called REFNOVA. REFNOVA allows customers to converts non-food plant residues into sustainable products such as biochar, activated carbon, biofuel, biopolymers and biochemicals. Our products help customers replace fossil based products and enable decarbonisation.
- Send — We're transforming commercial insurance software with our composable SaaS platform, which seamlessly scales and flexes to cover everything your team needs.
UCLB is the commercialisation company of UCL and its partner NHS Trusts. They bring to market truly world-leading, world-changing technologies, innovations that have a real and positive impact on people’s lives. UCLB the access point to the wealth of innovation and intellectual property emanating from UCL and partner hospitals including UniversityCollege Hospital, Great Ormond Street Hospital, Royal Free Hospital and Moorfields Eye Hospital. They offer a number of services to assist the technology development process, from consultancy through to collaborative research, IP licensing and the creation of spinout companies and joint ventures to maximise the commercial potential of new discoveries, materials and processes.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Seed, Series A, Pre-Seed
- Geography: United Kingdom
Investor stats
- Total investments: 18
- Round size: Seed $945k–$16M; Series A $1.8M–$2.7M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Hazy — Hazy is a UCL AI spin out backed by Microsoft and Nationwide. Our core product is synthetic data - data generated artificially using machine learning techniques, that retains the statistical properties of the real data and can be safely used for analytics and innovation without compromising customers privacy and confidential information. We do itby capturing patterns in the raw data to generate completely synthetic 'hazy' data that maintains the statistical value of the original. This means businesses can unlock their data for innovation freely with safer and faster data provisioning on demand and no compliance, security or privacy risks and procurement delays.
- Carbon Re — Carbon Re is a climate tech company using cutting-edge AI solutions to decarbonize cement and steel. Get in touch with us today!
- Astroscreen — Astroscreen protects brands and defends democracy from harmful social media manipulation campaigns
Impacting the future of medicine.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, The Netherlands
Investor stats
- Total investments: 117
- Round size: Series A $4.5M–$30M; Series B $12M–$115M; Series C $5.6M–$65M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Noema Pharma — BEYOND SYMPTOM CONTROL Developing therapies to help both orphan and larger patient populations with conditions of the brain and nervous system live their li ...
- Seamless Therapeutics — Seamless Therapeutics is changing the paradigm of gene editing through a pioneering approach to restore health in patients with severe conditions in a safe and precise manner. Seamless technology platform unlocks the reprogramming of recombinases, a highly versatile class of enzymes.
- Complement Therapeutics — Turning powerful new Complement System insights into innovative treatments Developing the next generation of complement medicines [chevron-down] Turning powerful new Complement System insights into innovative treatments Developing the next generation of complement medicines [chevron-down] Geographic atrophy (late dry age-related macular degeneration) is a chronic eye condition that affects millions - and for which there is
Medical VC funding in United Kingdom at a glance
Stats across 879 deals from 743 investors.
Access all 743 VC funds in United Kingdom Medical startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Medical VC Funds in United Kingdom investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 743 VC funds investing in United Kingdom Medical startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!